The reasons behind the IFN signature in SLE are (1) the existence of endogenous IFN inducers, (2) activation of several IFN-producing cell types, (3) production of many different IFNs, (4) a genetic setup promoting IFN production and (5) deficient negative feedback mechanisms.

2022年9月12日 · IFN-Score-B is able to differentiate the interferon signature in SLE and RA, can predict progression to SLE in ANA-positive at-risk individuals and can better predict response to...

Autoantibody formation and immune complex formation are important mediators in lupus pathogenesis, but an important role of the type I interferon (IFN) pathway has been identified in SLE patients and mouse models of lupus.

Type I IFN is implicated in SLE pathogenesis by multiple lines of evidence, including genetics, gene expression, and induction of SLE by IFN treatment. Nucleic-acid sensing pathways influence the threshold of activation and triggering of type I IFN production.

Skewing of type I interferon (IFN) production and responses is a hallmark of systemic lupus erythematosus (SLE). Genetic and environmental contributions to IFN production lead to aberrant innate and adaptive immune activation even before clinical development of disease.

In this review, we discuss the current understanding of IFNs in SLE, focusing on their regulation, the influence of genetic background, and environmental factors and therapies that are under development aiming to inhibit the type I IFN system in SLE.

2019年4月23日 · A role for interferon (IFN) in systemic lupus erythematosus (SLE) pathogenesis is inferred from the prominent IFN gene signature (IGS), but the major IFN species and its relationship to disease...

2024年5月21日 · Systemic lupus erythematosus (SLE) displays a hallmark interferon (IFN) signature. Yet, clinical trials targeting type I IFN (IFN-I) have shown variable efficacy, and blocking IFN-II failed to treat SLE. Here, we show that IFN type levels in SLE vary significantly across clinical and transcriptional endotypes.

2017年6月1日 · In this review, we discuss the current understanding of IFNs in SLE, focusing on their regulation, the influence of genetic background, and environmental factors and therapies that are under development aiming to inhibit the type I IFN system in SLE.

Purpose of review: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of systemic lupus erythematosus (SLE). Here, we focus on new developments in pathways of IFN-I stimulation, the role of IFN-I in syndromes associated with lupus-like diseases, the utility of IFN-I signatures as biomarkers, and the progress of therapeutic ...

2016年5月26日 · Type I interferon (IFN) is an attractive therapeutic target in systemic lupus erythematosus (SLE), a notion bolstered by the positive results of a recent clinical trial...

2025年3月7日 · The skin is the most commonly affected organ of patients with lupus ().Nonlesional skin of patients at risk for lupus exhibits robust IFN secretion even with minimal IFN signature in the blood (10–12).This cutaneous type I IFN production leads to increased epidermal cell death and inflammatory activation of myeloid cells and is widely accepted as a driver of CLE and DM lesions (3, 11, 13, 14).

2022年8月10日 · Due to the large overlap between IFN-α and IFN-γ, SLE is mostly characterized by expression of the IFN-α gene after onset. Therefore, the role of IFN-γ in SLE may be underestimated. This article mainly reviews the role of IFN-γ in SLE and focuses on the nonnegligible role of IFN-γ in SLE to gain a more comprehensive understanding of the ...

Dysregulation of type I interferons (IFNs) has been implicated in the pathogenesis of systemic lupus erythematosus (SLE) since the late 1970s. The majority of SLE patients demonstrate evidence of type I IFN pathway activation; however, studies ...

2020年12月1日 · Type I IFN is implicated in SLE pathogenesis by multiple lines of evidence, including genetics and induction of SLE by IFN treatment. Nucleic-acid sensing pathways influence the threshold of activation and triggering of type I IFN production.

2025年3月6日 · High levels of IFN-I (type 1 interferon) are present in most SLE patients, making this pathway an attractive target for drug development. Litifilimab downregulates IFN-I by targeting BDCA2, while dexadilimab targets ILT7 to recruit effector cells, reducing IFN-I production by killing PDCs. Anifrolumab binds to the IFN-I receptor, blocking the ...

2024年10月7日 · Opsonization of red blood cells that retain mitochondria (Mito + RBCs), a feature of systemic lupus erythematosus (SLE), triggers type I interferon (IFN) production in macrophages. We report that monocytes (Mos) co-produce IFN and mature interleukin-1β (mIL-1β) upon Mito + RBC opsonization.

2023年3月12日 · Elevated type I interferon signature (IFN- I) in SLE leads to dysregulation of innate and adaptive immune function, resulting in autoantibodies production. The most common method to determine IFN-I signature is measuring the gene expression of several IFN-α-inducible genes (IFIGs) in blood samples and calculating a score.

2024年1月9日 · Type 1 interferons (IFNs) play a central role in the development and disease course of systemic lupus erythematosus (SLE). In a new study, researchers explored SLE disease activity and type I interferon 4 gene signature (IFNGS), to better understand disease pathogenesis and clinical outcomes.

2020年10月17日 · Our findings suggest that interferon-related gene expression and pathways are common features for SLE pathogenesis, and IFN-<i>γ</i> and IFN-<i>γ</i>-inducible GBP1 gene in naive SLE were emphasized. Together, the identified genes and cellular pathways have expanded our understanding on the mechanis …